

บรรณานุกรม (Bibliography)

- Berumen J., Ordonez R.M., Lazcano E., Salmeron J., Galvan S.C., Estrada R.A., *et al.* Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control study. *J Natl Cancer Inst* 2001; 93(17): 1325-30.
- Chakrabarti O., Veeraraghavalu K., Tergaonkar V., Liu Y., Androphy E.J., Stanley M.A., *et al.* Human papillomavirus type 16 E6 amino acid 83 variants enhance E6-mediated MAPK signaling and differentially regulate tumorigenesis by notch signaling and oncogenic Ras. *J Virol* 2004; 78(11): 5934-45.
- Clifford G.M., Smith J.S., Plummer M., Munoz N., and Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. *Br J Cancer* 2003; 88(1): 63-73.
- Crook T., Tidy J.A., and Vousden K.H. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. *Cell* 1991; 67(3): 547-56.
- de Boer M.A., Peters L.A., Aziz M.F., Siregar B., Cornain S., Vrede M.A., *et al.* Human papillomavirus type 16 E6, E7, and L1 variants in cervical cancer in Indonesia, Suriname, and The Netherlands. *Gynecol Oncol* 2004; 94(2): 488-94.
- del Refugio Gonzalez-Losa M., Laviada Mier y Teran M.A., Puerto-Solis M., and Garcia-Carranca A. Molecular variants of HPV type 16 E6 among Mexican women with LSIL and invasive cancer. *J Clin Virol* 2004; 29(2): 95-8.
- Ellis J.R., Keating P.J., Baird J., Hounsell E.F., Renouf D.V., Rowe M., *et al.* The association of an HPV16 oncogene variant with HLA-B7 has implications for vaccine design in cervical cancer. *Nat Med* 1995; 1(5): 464-70.
- Filippova M., Song H., Connolly J.L., Dermody T.S., and Duerksen-Hughes P.J. The human papillomavirus 16 E6 protein binds to tumor necrosis factor (TNF) R1 and protects cells from TNF-induced apoptosis. *J Biol Chem* 2002; 277(24): 21730-9.
- Harris N., Brill E., Shohat O., Prokocimer M., Wolf D., Arai N., *et al.* Molecular basis for heterogeneity of the human p53 protein. *Mol Cell Biol* 1986; 6(12): 4650-6.
- Horikawa I., Cable P.L., Afshari C., and Barrett J.C. Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene. *Cancer Res* 1999; 59(4): 826-30.

- Kang S., Jeon Y.T., Kim J.W., Park N.H., Song Y.S., Kang S.B., *et al.* Polymorphism in the E6 gene of human papillomavirus type 16 in the cervical tissues of Korean women. *Int J Gynecol Cancer* 2005; 15(1): 107-12.
- Kast W.M., Brandt R.M., Sidney J., Drijfhout J.W., Kubo R.T., Grey H.M., *et al.* Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. *J Immunol* 1994; 152(8): 3904-12.
- Kim N.W., Piatyszek M.A., Prowse K.R., Harley C.B., West M.D., Ho P.L., *et al.* Specific association of human telomerase activity with immortal cells and cancer. *Science* 1994; 266(5193): 2011-5.
- Moscicki A.B., Hills N., Shiboski S., Powell K., Jay N., Hanson E., *et al.* Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. *Jama* 2001; 285(23): 2995-3002.
- Nash J.D., Burke T.W., and Hoskins W.J. Biologic course of cervical human papillomavirus infection. *Obstet Gynecol* 1987; 69(2): 160-2.
- Pientong C., Ekalaksananan T., Kongyingyoes B., Kritpetcharat O., Swadpanich U., Pengsa P., *et al.* Immunocytochemical staining of p16INK4a protein from conventional Pap test and its association with human papillomavirus infection. *Diagn Cytopathol* 2004; 31(4): 235-42.
- Qiu A.D., Wu E.Q., Yu X.H., Jiang C.L., Jin Y.H., Wu Y.G., *et al.* HPV prevalence, E6 sequence variation and physical state of HPV16 isolates from patients with cervical cancer in Sichuan, China. *Gynecol Oncol* 2007; 104(1): 77-85.
- Radhakrishna Pillai M., Sreevidya S., Pollock B.H., Jayaprakash P.G., and Herman B. Human papillomavirus type 16 E6 and E7 gene variations in Indian cervical cancer. *Gynecol Oncol* 2002; 87(3): 268-73.
- Schlecht N.F., Platt R.W., Duarte-Franco E., Costa M.C., Sobrinho J.P., Prado J.C., *et al.* Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. *J Natl Cancer Inst* 2003; 95(17): 1336-43.
- Stoppler M.C., Ching K., Stoppler H., Clancy K., Schlegel R., and Icenogle J. Natural variants of the human papillomavirus type 16 E6 protein differ in their abilities to alter keratinocyte differentiation and to induce p53 degradation. *J Virol* 1996; 70(10): 6987-93.
- Tornesello M.L., Duraturo M.L., Salatiello I., Buonaguro L., Losito S., Botti G., *et al.* Analysis of human papillomavirus type-16 variants in Italian women with cervical intraepithelial neoplasia and cervical cancer. *J Med Virol* 2004; 74(1): 117-26.

Yamada T., Manos M.M., Peto J., Greer C.E., Munoz N., Bosch F.X., *et al.* Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective. *J Virol* 1997; 71(3): 2463-72.

Zehbe I., Wilander E., Delius H., and Tommasino M. Human papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma than the prototype. *Cancer Res* 1998; 58(4): 829-33.



